• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].

作者信息

Rexer H, Hammerer P

机构信息

AUO Geschäftsstelle, MeckEvidence - Dienstleistungen für medizinische Dokumentation und Forschung, Seestr. 11, 17252, Schwarz, Deutschland.

Städtisches Klinikum Braunschweig, Braunschweig, Deutschland.

出版信息

Urologe A. 2016 Mar;55(3):395-7. doi: 10.1007/s00120-016-0032-6.

DOI:10.1007/s00120-016-0032-6
PMID:26820656
Abstract
摘要

相似文献

1
[A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].[ARN-509用于非转移性（M0）去势抵抗性前列腺癌男性患者的多中心、随机、双盲、安慰剂对照III期研究（SPARTAN）：AUO研究AP 82/14]
Urologe A. 2016 Mar;55(3):395-7. doi: 10.1007/s00120-016-0032-6.
2
[Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].局部或局部晚期前列腺癌的III期研究：阿帕他胺用于接受原发性放疗的局部高危前列腺癌或局部晚期前列腺癌患者的随机、双盲、安慰剂对照3期研究（ATLAS）——AUO的AP 90/15研究
Urologe A. 2017 Feb;56(2):243-244. doi: 10.1007/s00120-017-0329-0.
3
Apalutamide: A new agent in the management of prostate cancer.阿帕鲁胺：前列腺癌治疗的新药物。
J Oncol Pharm Pract. 2019 Dec;25(8):1968-1978. doi: 10.1177/1078155219864424. Epub 2019 Jul 30.
4
Apalutamide shows efficacy in prostate cancer.阿帕鲁胺在前列腺癌中显示出疗效。
Lancet Oncol. 2018 Mar;19(3):e149. doi: 10.1016/S1470-2045(18)30156-6. Epub 2018 Feb 16.
5
[Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for first line chemotherapy (VIABLE) - AUO study AP 78/13].
Urologe A. 2015 Apr;54(4):555-7. doi: 10.1007/s00120-015-3801-8.
6
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.三期、随机、安慰剂对照研究每日口服 Zibotentan（ZD4054）治疗非转移性去势抵抗性前列腺癌患者。
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):187-92. doi: 10.1038/pcan.2013.2. Epub 2013 Feb 5.
7
[Non-interventional study of metastatic castration-resistant prostate cancer. Prospective, non-interventional trial on the influence of adherence to abiraterone treatment in patients with metastatic, castrate-resistant prostate cancer (IMPACT) - trial AP 76/13 of the AUO].转移性去势抵抗性前列腺癌的非干预性研究。关于转移性去势抵抗性前列腺癌患者阿比特龙治疗依从性影响的前瞻性非干预性试验（IMPACT）——AUO的AP 76/13试验
Urologe A. 2015 Jul;54(7):1021-2. doi: 10.1007/s00120-015-3869-1.
8
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.多西他赛和泼尼松联合或不联合来那度胺治疗化疗初治转移性去势抵抗性前列腺癌患者（MAINSAIL）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2. Epub 2015 Mar 3.
9
[Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]].
Urologe A. 2014 Nov;53(11):1665-7. doi: 10.1007/s00120-014-3643-9.
10
Drug therapies for metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌的药物治疗
Future Oncol. 2015;11(17):2395-403. doi: 10.2217/fon.15.168. Epub 2015 Aug 14.

引用本文的文献

1
Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.阿帕鲁胺：用于治疗非转移性去势抵抗性前列腺癌的药物。
Drugs. 2019 Sep;79(14):1591-1598. doi: 10.1007/s40265-019-01194-x.
2
The impact of time to metastasis on overall survival in patients with prostate cancer.转移性前列腺癌患者的转移时间对总生存期的影响。
World J Urol. 2018 Jul;36(7):1039-1046. doi: 10.1007/s00345-018-2236-4. Epub 2018 Feb 27.